Abstract
To determine whether integration of human papillomavirus (HPV) DNA sequences could lead to the deregulation of genes implied in oncogenesis, we analysed the HPV integration sites in a series of nine cell lines derived from invasive genital carcinomas. Using in situ hybridization, HPV16 or 18 sequences were found at chromosome band 8q24, the localization of MYC, in IC1, IC2, IC3, IC6 and CAC-1 cells and at other sites in IC4, IC5, IC7 and IC8 cells. We then localized viral sequences at the molecular level and searched for alterations of MYC structure and expression in these cells. MYC genomic status and viral integration sites were also analysed in primary tumors from which IC1, IC2, IC3 and IC6 cells were derived. In IC1, IC2 and CAC-1 cells, HPV DNA was located within 58 kb of MYC, downstream, upstream, or within MYC. In IC3 and IC6 cells, HPV DNA was located 400–500 kb upstream of MYC. Amplification studies showed that, in IC1, IC2 and IC3, viral and MYC sequences were co-amplified in an amplicon between less than 50 and 800 kb in size. MYC amplification was also observed in primary tumors, indicating that this genetic alteration, together with viral insertion at the MYC locus, had already taken place in vivo. MYC was not amplified in the other cell lines. MYC mRNA and protein overexpression was observed in the five cell lines in which the HPV DNA was inserted close to the MYC locus, but in none of the lines where the insertion had occurred at other sites. MYC activation, triggered by the insertion of HPV DNA sequences, can be an important genetic event in cervical oncogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Alonso L, Fuchs E . (2003). Proc Natl Acad Sci USA 100 (Suppl 1): 11830–11835.
Bosch FX, Manos M, Munoz N, Sherman M, Jansen AM, Peto J et al. (1995). J Natl Cancer Inst 87: 796–802.
Bouallaga I, Massicard S, Yaniv M, Thierry F . (2000). EMBO Rep 1: 422–427.
Brink AA, Wiegant JC, Szuhai K, Tanke HJ, Kenter GG, Fleuren GJ et al. (2002). Cancer Genet Cytogenet 134: 145–150.
Cappellen D, De Oliveira C, Ricol D, Gil Diez de Medina S, Bourdin J, Sastre-Garau X et al. (1999). Nat Genet 23: 18–20.
Couturier J, Sastre-Garau X, Schneider-Maunoury S, Labib A, Orth G . (1991). J Virol 65: 4534–4538.
Crook T, Storey A, Almond N, Osborn K, Crawford L . (1988). Proc Natl Acad Sci USA 85: 8820–8824.
Cullen AP, Reid R, Campion M, Lörincz AT . (1991). J Virol 65: 606–612.
Dang CV . (1999). Mol Cell Biol 19: 1–11.
Daniel R, Katz RA, Skalka AM . (1999). Science 284: 644–647.
Dürst M, Croce CM, Gissmann L, Schwarz E, Huebner K . (1987). Proc Natl Acad Sci USA 84: 1070–1074.
Ferber MJ, Montoya DP, Yu C, Aderca I, McGee A, Thorland EC et al. (2003a). Oncogene 22: 3813–3820.
Ferber MJ, Thorland EC, Brink AA, Rapp AK, Phillips LA, McGovern R et al. (2003b). Oncogene 22: 7233–7242.
Fourel G, Couturier J, Wei Y, Apiou F, Tiollais P, Buendia M . (1994). EMBO J 13: 2526–2534.
Frye M, Gardner C, Li ER, Arnold I, Watt FM . (2003). Development 130: 2793–2808.
Gandarillas A, Watt FM . (1997). Genes Dev 11: 2869–2882.
Halbert CL, Demers GW, Galloway DA . (1991). J Virol 65: 473–478.
Hayakawa O, Kudo R, Koizumi M, Yamauchi O, Yamamoto H, Takehara M . (1988). Sapporo Igaku Zasshi 57: 603–611.
Henglein B, Synovzik H, Groitl P, Bornkamm G, Hartl P, Lipp M . (1989). Mol Cell Biol 9: 2105–2113.
Herrick J, Conti C, Teissier S, Thierry F, Couturier J, Sastre-Garau X et al. (2005). Cancer Res 65: 1174–1179.
Hori T, Ichimura H, Minamihisamatsu M, Takahashi E, Yamauchi M, Hama Y et al. (1991). Jap J Cancer Res 82: 371–375.
Jeon S, Lambert P . (1995). Proc Natl Acad Sci USA 92: 1654–1658.
Jiko K, Tsuda H, Sato S, Hirohashi S . (1994). Int J Cancer 59: 601–606.
Joos S, Haluska F, Falk M, Henglein B, Hameister H, Croce C et al. (1992). Cancer Res 52: 6547–6552.
Kalantari M, Blennow E, Hagmar B, Johansson B . (2001). Diagn Mol Pathol 10: 46–54.
Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A et al. (1999). Cancer Res 59: 6132–6136.
Klimov E, Vinokourova S, Moisjak E, Rakhmanaliev E, Kobseva V, Laimins L et al. (2002). BMC Cancer 2: 24.
Kraus I, Ziegert C, Koch T, Schneider A, Dürst M . (2005). 22nd International Papillomavirus Conference and Clinical Workshop, Vol. P-023. UCSF: Vancouver, pp 157.
Lazo P, DiPaolo J, Popescu N . (1989). Cancer Res 49: 4305–4310.
Livak KJ, Schmittgen TD . (2001). Methods 25: 402–408.
Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordière A, Clough K et al (1998). J Clin Oncol 16: 2613–2619.
Luft F, Klaes R, Nees M, Dürst M, Heilmann V, Melsheimer P et al. (2001). Int J Cancer 92: 9–17.
Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M et al. (2004). J Virol 78: 11451–11460.
Münger K, Werness B, Dyson N, Phelps W, Harlow E, Howley M . (1989). EMBO J 8: 4099–4105.
Nesbit C, Tersak J, Prochownik E . (1999). Oncogene 18: 3004–3016.
Nurnberg W, Artuc M, Nawrath M, Lovric J, Stuting S, Moelling K et al. (1995). Cancer Res 55: 4432–4437.
Pei XF, Meck JM, Greenhalgh D, Schlegel R . (1993). Virology 196: 855–860.
Pelengaris S, Khan M, Evan G . (2002). Nat Rev Cancer 2: 764–776.
Pelengaris S, Littlewood T, Khan M, Elia G, Evan G . (1999). Mol Cell 3: 565–577.
Popescu N, DiPaolo J, Amsbaugh S . (1987). Cytogenet Cell Genet 44: 58–62.
Reuter S, Bartelmann M, Vogt M, Geisen C, Napierski I, Kahn T et al. (1998). EMBO J 17.
Riou G, Barrois M, Sheng Z, Duvillard P, Lhomme C . (1988). Oncogene 3: 329–333.
Riou G, Lê M, Le Doussal V, Barrois M, George M, Hair C . (1987). The Lancet, 761–763.
Roix JJ, McQueen PG, Munson PJ, Parada LA, Misteli T . (2003). Nat Genet 34: 287–291.
Rosty C, Aubriot MH, Cappellen D, Bourdin J, Cartier I, Thiery JP et al. (2005a). Mol Cancer 4: 15.
Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M et al. (2005b). Oncogene.
Sastre-Garau X, Favre M, Couturier J, Orth G . (2000). J Gen Virol 81: 1983–1993.
Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F . (2002). Cell 110: 521–529.
Schwarz E, Freese U, Gissmann L, Mayer W, Roggenbuck B, Stremlau A et al. (1985). Nature 314: 114.
Selten G, Cuypers H, Zijlstra M, Melief C, Berns A . (1984). EMBO J 3: 3215–3222.
Stracker TH, Carson CT, Weitzman MD . (2002). Nature 418: 348–352.
Thorland E, Myers S, Persing D, Sarkar G, McGovern R, Gostout B et al. (2000). Cancer Res 60: 5916–5921.
Thorland EC, Myers SL, Gostout BS, Smith DI . (2003). Oncogene 22: 1225–1237.
Veldman T, Liu X, Yuan H, Schlegel R . (2003). Proc Natl Acad Sci USA 100: 8211–8216.
Waikel RL, Kawachi Y, Waikel PA, Wang XJ, Roop DR . (2001). Nat Genet 28: 165–168.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. (1999). J Pathol 189: 12–19.
Wentzensen N, Ridder R, Klaes R, Vinokurova S, Schaefer U, Doeberitz MK . (2002). Oncogene 21: 419–426.
Wentzensen N, Vinokurova S, von Knebel Doeberitz M . (2004). Cancer Res 64: 3878–3884.
Wilke C, Hall B, Hoge A, Paradee W, Smith D, Glover T . (1996). Hum Mol Genet 5: 187–195.
Wu X, Li Y, Crise B, Burgess SM . (2003). Science 300: 1749–1751.
Zeidler R, Joos S, Delecluse H, Klobeck G, Vuillaume M, Lenoir G et al. (1994). Genes Chromosomes Cancer 9: 282–287.
Zhang A, Maner S, Betz R, Angstrom T, Stendahl U, Bergman F et al. (2002). Int J Cancer 101: 427–433.
Ziegert C, Wentzensen N, Vinokurova S, Kisseljov F, Einenkel J, Hoeckel M et al. (2003). Oncogene 22: 3977–3984.
Acknowledgements
We thank Zofia Maciorowski and Edith Heard for their help in preparation of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Peter, M., Rosty, C., Couturier, J. et al. MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene 25, 5985–5993 (2006). https://doi.org/10.1038/sj.onc.1209625
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209625
Keywords
This article is cited by
-
Characteristics of HPV integration in cervical adenocarcinoma and squamous carcinoma
Journal of Cancer Research and Clinical Oncology (2023)
-
Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer
Medical Oncology (2023)
-
HPV18 oncoproteins driven expression of PKM2 reprograms HeLa cell metabolism to maintain aerobic glycolysis and viability
VirusDisease (2022)
-
HPV positive neuroendocrine cervical cancer cells are dependent on Myc but not E6/E7 viral oncogenes
Scientific Reports (2017)
-
Amplification of EGFR and cyclin D1 genes associated with human papillomavirus infection in oral squamous cell carcinoma
Medical Oncology (2017)